The CAB serves as a strategic resource to Cellectis as the Company enters the clinical development of allogeneic CAR T immunotherapies.
Pr Catherine Bollard, Chief, Division of Allergy and Immunology at the Children’s Research Institute, Children's National Health System and The George Washington University, Washington DC
Professor Catherine Bollard, MBChB, MD, FRACP, FRCPA, is Chief, Division of Allergy and Immunology and Director of the Program for Cell Enhancements and Technologies for Immunotherapy at the Children’s Research Institute, Children's National Health System and The George Washington University. A distinguished hematologist and immunotherapist, Dr. Bollard’s research interests focus on areas that include developing cell and gene therapies for patients with cancer and underlying immune deficiencies.
Pr Hervé Dombret, Head of the Leukemia Unit at the Hôpital Saint Louis, Paris, and Director of Clinical Research in the Hematology, Immunology and Transplantation Unit, University of Paris Diderot, Paris, France
Professor Hervé Dombret, MD, is Head of the Leukemia Unit at the Hôpital Saint Louis, Paris, and Director of Clinical Research in the Hematology, Immunology and Transplantation Unit, University of Paris Diderot. He is also Director of the University Hematology Research Center in Hôpital Saint-Louis and has a PhD in Oncogenesis. His main fields of interest include clinical and translational research in acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes and chronic myeloid leukemia.
Pr John Gribben, Lead of the Centre for Hemato-Oncology, Barts Cancer Institute of London, UK
Professor Gribben holds the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London, where his research group is currently focused on immunological approaches to the treatment of hematological cancers. He was a research fellow at University College London and Dana-Farber Cancer Institute, Harvard Medical School. He joined the faculty at Harvard Medical School, the Dana-Farber Cancer Institute and Brigham and Women's Hospital in 1992. He is a founding member of the CLL Research Consortium, was Associate Editor of Blood from 2008-2014 and was elected a Fellow of the Academy of Medical Science. He will be President–Elect of The European Hematology Association (EHA) from 2017 to 2019.
Pr Ola Landgren, Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, New York, NY
Professor Ola Landgren, MD, is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center New York and Professor of Medicine at Weill Cornell Medical College. He is a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring. He has a strong interest in the development of early-treatment clinical trials, targeting high-risk smoldering myeloma. He develops new strategies (including cell-based, molecular-based and imaging-based) and implements advanced MRD testing in clinical trials at MSK.
Dr Marcela Maus, Director of Cellular Immunotherapy at the Massachusetts General Hospital, Boston, MA
Doctor Marcela V. Maus, MD, PhD, is Director of Cellular Immunotherapy at the Massachusetts General Hospital in Boston and Assistant Professor at Harvard Medical School. She is a board-certified hematologist-oncologist with extensive research experience in all aspects of pre-clinical and clinical design and use of cell therapies and gene-modified T-cells for cancer. Dr Maus completed undergraduate studies at MIT and her MD and PhD at Penn. As a graduate student, she worked with Dr. Carl June on the biology of human T cell activation. She completed residency training in internal medicine at the University of Pennsylvania Health System, and completed fellowship training in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center. Her research focuses on the pre-clinical development and clinical translation of engineered T cell therapies.
Pr Dietger Niederwieser, Professor of Medicine, Head of the Division of Hematology and Medical Oncology at the University of Leipzig, Germany
Professor Dietger Niederwieser, MD, is Professor of Medicine, Head of the Division of Hematology and Medical Oncology at University of Leipzig and University Hospital. His therapeutic areas of expertise include Clinical Immunology, Hematology and Oncology, and his research is focused on stem cell transplantation, cell therapies and gene therapies. He has extensive experience in health economics, outcomes research, clinical development of innovative drugs and clinical studies.
Pr Kanti Rai, Professor of Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, USA
Professor Rai, an internationally renowned leukemia researcher and hematologist, brings extensive knowledge and experience from his 50-year career spanning groundbreaking clinical leukemia research. He is the Joel Finkelstein Cancer Foundation Professor of Medicine at the Hofstra North Shore-LIJ School of Medicine, where he is also Professor of Molecular Medicine. He is currently Chief of the Chronic Lymphocytic Leukemia (CLL) Research and Treatment Program at Northwell Cancer Institute and an Investigator at The Feinstein Institute for Medical Research.
Pr Catherine Thieblemont, Professor of Hematology in the Paris VII- University, France and Head of the Hemato-Oncology Unit of St-Louis Hospital in Paris
Professor Thieblemont is Professor of Hematology in the Paris VII- University, France, and Head of the Hemato-Oncology Department in the Hospital Saint-Louis – Paris, France, where she develops specific therapeutic programs for refractory/relapsed lymphomas and chronic lymphocytic leukemia. She belongs to the administrative and scientific committees of the LYSA, the lymphoma study association, to the board of directors of the IELSG, the International extranodal lymphoma study association, and to the Fellowships and Grants Committee of The European Hematology Association (EHA).
Pr Koen van Besien, Director of the Stem Cell Transplant Program and Professor of Medicine at Weill Cornell Medical College, NYC, USA
Professor van Besien serves as Director of the Stem Cell Transplant Program at Weill Cornell Medical Center and is an Attending Physician at New York Presbyterian Hospital. A graduate of the College ND de la Paix in Namur, Belgium, and University of Leuven, Belgium. Professor van Besien also holds a PhD from the University of Maastricht in the Netherlands. He completed a hematology/oncology fellowship at Indiana University and in Bruges, Belgium, and was a faculty member of the transplant program at MD Anderson Cancer Center. The Professor also directed the transplant program at the University of Illinois and the transplant and lymphoma programs at the University of Chicago. He is Editor-in-chief of Leukemia and Lymphoma.